

GEORGE J. MURAKAWA, M.D., Ph.D.

Office Address:

Somerset Skin Centre
DermCenter
255 Kirts Blvd
Troy, MI, 48084
248-244-8448
248-244-8766 (fax)
Michigan license: 4301077180

PERSONAL DATA:

Birthplace: Anaheim, CA
Marital Status: Married to Mimi, son Ryan, daughter Megan

EDUCATION:

University of California, Los Angeles	B.A.—Microbiology	1983
University of California, Los Angeles	Ph.D.—Microbiology	1988
Harvard Medical School	M.D.	1992

TRAINING:

Postdoct. Fellow, Dept. Mol. Biol., Harvard U, Richard Selden, MD, PhD, Adv. Studied expression of human insulin in transgenic mice.	9/88-7/90
Medical Student Fellow, Dept. Pathology, Beth Israel Hospital	7/90-2/91
Intern, Medicine, University of California, San Diego	6/92-6/93
Resident, Dermatology, University of California, San Francisco	7/93-6/95
Fellow, Dermatology, University of California, San Francisco	7/95-6/97
Postdoctoral Fellow, Dept. Microbio. & Immunol., Stanford University Lucy Tompkins, MD, PhD, Stanley Falkow, PhD, Advisors Studied pathogenesis of <i>Bartonellae henselae</i> (cat scratch disease and BA)	7/95-6/98
Postdoct. Fellow/Clin. Instruct., Dermatol., UCSF, Peter Elias, MD, Advisor Develop artificial skin systems to study <i>Staphylococcus aureus</i> /skin interactions.	8/97-6/98
Clinical Trials: Fundamentals of Clinical Research, ACRP course, Alexandria, VA	1999
NIH course: “Human Participants Protection Education for Research Teams”	Jan. 2008
NIH course: “Protecting Human Research Participants”	1/6/2010

FACULTY APPOINTMENTS:

Clinical Instructor, Dermatology, University of California, San Francisco	7/97-6/98
Clinical Instructor, Dermatology, Stanford University	7/96-6/98
Assistant Professor, Dermatology, Albany Medical College, NY	6/98-10/00
Chief, Division Dermatology, Albany Medical College, NY	6/98-10/00
Associate Professor, Dermatology, Wayne State University, Detroit, MI	9/00-12/04
Chair, Department of Dermatology, Wayne State University, Detroit, MI	9/00-12/04
Clinical Professor, Department of Internal Medicine, Michigan State University	6/05-Present

HOSPITAL/PROFESSIONAL APPOINTMENTS:

AIDS Dermatologist, Haight-Ashbury Free Clinic, San Francisco, CA	1/97-6/98
Chief, Division Dermatology, Albany Medical College, NY	6/98-10/00
Residency Director, Div. Dermatology, Albany Medical College, Albany, NY	6/98-10/00
Director, Residency Selection Committee, Div. Dermatology, AMC	6/98-10/00
Director, Phototherapy Unit, Div. Dermatol., AMC	6/98-10/00
Director, Cutaneous T-Cell Lymphoma Clinic, Div. Dermatology, AMC	2/99-10/00

Consultant, Photopheresis Unit, AMC	3/99-10/00
Director, Dermatologic Surgery, Div. Dermatology, AMC	2/99-10/00
Chair, Department of Dermatology, Wayne State University, Detroit, MI	9/00-12/04
Residency Director, Dept. Dermatol, Wayne State University, Detroit, MI	9/00-12/04
Director, Residency Selection Committee, Dept. Dermatol., Wayne State University, Detroit, MI	9/00-12/04
Specialist-In-Chief, Dermatology, Detroit Medical Center	10/00-12/04
Specialist-In-Chief, Dermatology, Harper Hospital	10/00-6/05
Dermatologist, Karmanos Cancer Institute	2002-2005
President, University Dermatology	10/00-12/04
President, Laser Leasing Corporation	3/03-Present
President, DermCenter	1/04-Present
President, 255 Kirts LLC	3/04-Present
President, Somerset Skin Centre	1/05-Present

MAJOR PROFESSIONAL SOCIETIES:

American Academy of Dermatology (1996-Present)
 Association of Professors of Dermatology (1998-Present)
 Capital District Dermatologic Society (1998-2000)
 Dermatology Foundation (1996-Present)
 Dermatology Teachers Exchange Group (1998-Present)
 Medical Dermatological Society (1999-Present)
 New England Cutaneous Lymphoma Group (1999-2000)
 New England Dermatological Society (1998-2000)
 New York State Dermatologic Society (1998-2000)
 Society of Investigative Dermatology (1995-Present)
 Michigan State Dermatological Society (2000-Present)
 Michigan State Medical Society (2000-Present)
 American Society for Dermatologic Surgery (2003-Present)
 American Society for Mohs Surgery (2004-Present)

LICENSURE AND BOARD CERTIFICATION:

Board of Medical License, Michigan #4301077180
 Medical Board of California
 New York Medical Board
 Diplomate, American Board of Dermatology, 1996. Recertified 2005

HONORS/AWARDS

Teacher of the Year, Department of Dermatology, Wayne State University	2002
Albert M. Kligman Fellow	1997
American Academy of Dermatology Young Investigator's Award	1997
Howard Hughes Medical Institute Postdoctoral Fellow	1996-1998
Postdoctoral Fellow National Research Service Award in Dermatology, UCSF	1995-96
Medical Student Fellow in Pathology--Beth Israel Hospital	1990-91
Dr. Ursula Mandel Fellow—UCLA	1987-88
Predocotrual Fellow National Research Service Award in Genetics—UCLA	1984-87

SERVICE:

Patient care

- Participate in skin screening sessions in the community
 - AAD skin cancer screening, Albany, NY, 1998-2000
 - Detroit Festival of the Arts, 2002-2005
 - Karmanos Cancer Institute, semiannual, 2000-2005
 - Crittenton Hospital Annual Skin Screen, 2004-Present
 - Madison Heights Senior Citizens Center 2005
 - City of Troy Free Health Care Screening 2007-8

Lectures for the community

Skin Cancer, AMC Cancer Center Monthly Health Forum, AMC, 5/18/99, 5/2000
Skin Cancer, Keynote Speaker, Lend-A-Helping-Hand Charity Golf Event, 6/25/2003
Skin Cancer, Lunch lecture series, CompuWare, 5/25/2003
Making Connections: Psoriasis; Renaissance Center, 6/1/4

Public speaking

Radio, TV appearances for skin-related issues

Professional consultation

Member, Data Safety Monitoring Board, Biotest, 2008-Present
Member IRB, United Physicians Research Institute, 2007-2009
Advisory Board, Abbott Laboratories, 10-03 to Present
Grant reviewer, Henry Ford Hospital Internal Grants, 10-03
NIH Grant Reviewer, Center for Scientific Review (ZRG1 SSS-G (02) Special Emphasis Panel) 1999
Board Question Writer, American Board of Dermatology, 1999-Present
Consultant, Ferndale Laboratories, 2001-Present
Speaker's Bureau: Novartis, Janssen, Ligand, Fujisawa, Amgen, Ferndale

External reviewer, Department of Dermatology, University of Cincinnati, 6-05

Journal/Editorial activity

Reviewer, Archives of Dermatology, 1999-Present
Reviewer, Journal of American Academy of Dermatology, 1999-Present
Editorial Board, Journal of American Academy of Dermatology, 2004-2009
Reviewer, Journal of the Neurological Sciences, 2000-2008
Reviewer, Pediatric Dermatology, 2002-Present
Reviewer, International Journal of Dermatology, 2002-2007
Reviewer, British Journal of Dermatology, 2004-Present
Reviewer, Journal of Investigative Dermatology, 2004-Present
Reviewer, Journal of Dermatological Treatment, 2004-Present

Other professionally related service

Director, Annual Dermatology Teaching Day, Albany Medical College, 1999-2000
Director, Primary Care Preceptorship in Dermatology 10/15/99
Director, Michigan Dermatologic Society Annual Meeting, Wayne St., 2000-4

National boards and committees

New York Delegate for Dermatology, New York State Medical Society, 1999-2000
American Academy of Dermatology:
AAD Committee: Research Working Group, Dermatology in the 21st Century
Board of Trustees, Sulzberger Institute for Dermatologic Education, 2003-2008
Core Curriculum Task Force, 2003-2008
Health Care Finance Committee, 2004-2008
Coding and Reimbursement Task Force, 2008-Present
Government Affairs, Policy, and Practice Committee, AAD Solutions Summit, 4/15-16/5
Dermatology Advocacy Network Legislative Conference, Washington DC, 9/7-9/08

Committees:

Wayne State University
Council of Clinical Chairs, 2000-4
University Physicians Group Board of Directors, 2000-4
UPG Finance Committee, 2002-2003
University Physicians Services, Executive Committee, 2002-2003
Detroit Medical Center
DMC Medical Executive Committee, 2000-4
Medical Staff Operations Committee, Harper Hospital, 2002-2004
Wayne County Medical Society Executive Committee, 2003-Present
WCMS Young Physicians Group, 2003-Present

TEACHING:

Wayne State University – School of Medicine

2000-4

Courses taught at Wayne State:

Pathophysiology course (2nd yr med student course)
Dermatology Theme—Director (10 hrs lecture) 2003-4
Connective Tissue/Dermatology Theme—Director, Dermatology section 2001-3
Clinical Dermatology (3rd, 4th yr med student course)—Course Director 2000-4
Dermatology Residency Program (didactic sessions)

Morphology session (weekly)	2000-4
Clinical textbook review (weekly)	2000-4
Basic science review (weekly)	2000-4
Inpatient rounds (monthly)	2000-4
Lectures (monthly)	2000-4
Course/Curriculum development:	
Dermatology Residency Director	2000-4
Pathophysiology course (2 nd yr med student course)	
Dermatology Theme—Director (10 hrs lecture)	2003-4
Connective Tissue/Dermatology Theme—Director, Dermatology section	2001-3
Clinical Dermatology (3 rd , 4 th yr med student course)—Course Director	2000-4
Other Teaching	
Medicine Teaching Conference, Beaumont Hospital (semiannual—AIDS derm, skin cancers)	2003-Present
Medicine Teaching Conference, St. John Hospital (annual)	2003-Present

Albany Medical College

1998-2000

Courses taught (Course Director for each program):

- Integument, Musculoskeletal II Theme (2nd yr med. student course)
- Clinical Dermatology 07-03-4001 (3rd, 4th yr elective rotation)
- Dermatology Residency Program (didactic sessions)
 - Morphology session (weekly)
 - Clinical textbook review (weekly)
 - Basic science review (weekly)
 - Inpatient rounds (monthly)
 - Lectures (monthly)
 - Journal Club (weekly)

Course/Curriculum development:

- Integument, Musculoskeletal II Theme (2nd yr med. student course)
- Clinical Dermatology 07-03-4001 (3rd, 4th yr elective rotation)
- Annual Dermatology Teaching Day, Albany Medical College, 1999-2000
- Primary Care Preceptorship in Dermatology 10/15/99

GRANT SUPPORT:

1. Principal Investigator, Association of Professors of Dermatology; APD Initiative to Promote Graduate and Undergraduate Education: *Development of a systems-based practice curriculum*. \$2,000; 2004.
2. Principal Investigator, BCBSM Foundation; 2004 Foundation Grant: Indigent care issues in dermatology; \$10,000; 2/1/4-1/31/5.
3. Principal Investigator, Dermatology Foundation; *2002 Research Grant: Keratinocyte Cytokine Responses to Staphylococcus aureus infections*; \$20,000; 7/1/02-6/30/03.
4. Principal Investigator, Dermatology Foundation; *2001 Program Development Grant*; \$10,000; 7/1/01-6/30/02.
5. Principal Investigator, NIH/National Institute of Arthritis & Musculoskeletal Skin Diseases; *Staphylococcus aureus Pathogenesis in Cutaneous Disease*; \$516,095, 7/1/99-6/30/04.
6. Principal Investigator, Dermatology Foundation; *Development of Artificial Skin Systems to Study Bacterial Pathogenesis*; \$10,000; 10/23/00-06/30/01.
7. Principal Investigator, Dermatology Foundation; Clinical Career Development Award; \$80,000; 7/99-6/00.
8. Principal Investigator, REAC (Research Evaluation Allocation Committee) grant, UCSF; \$10,000; 1998.
9. Principal Investigator, Howard Hughes Medical Institute Postdoctoral Fellow, \$155,500, 1996-1998.
10. Principal Investigator, Postdoctoral Fellow National Research Service Award in Dermatology, UCSF, \$25,000, 1995-1996.

Clinical Trials

- 1 Principal Investigator, Boehringer-Ingelheim, “*BI655066 Versus Ustekinumab and Placebo Comparators in a Randomized, Double-Blind Trial for Maintenance use in Moderate to Severe Plaque Type Psoriasis*”, February 2016
- 2 Principal Investigator, Novan Therapeutics, “*A Phase 3, Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing Efficacy, Tolerability and Safety of Once Daily S8204 and Vehicle Gel in the Treatment of Acne Vulgaris*”, February 2016

- 3 Principal Investigator, Regeneron Pharmaceuticals, Inc., “A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis”, April 2015
- 4 Principal Investigator, Regeneron Pharmaceuticals, Inc., “A Phase 3 Confirmatory Study Investigating The Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate to Severe Atopic Dermatitis”, February, 2015
- 5 Principal Investigator, Janssen R&D, “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis”, January, 2015
- 6 Principal Investigator, Janssen R&D, “A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab”, January, 2015
- 7 Principal Investigator, Roche, “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients with Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids”, March, 2015
- 8 Regeneron Pharmaceuticals, Inc., “An Open-Label Study of Dupilumab in Patients with Atopic Dermatitis who Participated in Previous Dupilumab Clinical Trials.”, July 2014
- 9 Principal Investigator, Novartis, “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of Treatment, Compared to Placebo and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects with Moderate to Severe Scalp Psoriasis”, October, 2014
- 10 Principal Investigator, Xenoport, Inc., “A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects with Chronic Plaque-Type Psoriasis”, July, 2014
- 11 Principal Investigator, Regeneron Pharmaceuticals, Inc., “A Randomized, Double-Blind, Placebo-Controlled Study Investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis Treated with Dupilumab”, August, 2014
- 12 Principal Investigator, Anacor “A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis”
- 13 Principal Investigator, Allergan “A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle control in Patients with Acne Vulgaris” (December, 2013)
- 14 Principal Investigator, Regeneron Pharmaceuticals, Inc., “Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis, May 2013
- 15 Principal Investigator, Merck, Sharpe & Dohme Corp, “A Study to Evaluate the Efficacy and Safety of Subcutaneous SCH 900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants with Moderate-to-Severe Chronic Plaque Psoriasis”, March 2013
- 16 Principal Investigator, Galderma R & D, “Dose Range Study of CD5789 in Acne Vulgaris”, June 2012
- 17 Principal Investigator, Janssen Biotech, Inc, “A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a “Subject-tailored” Maintenance Dosing Approach in Subjects with Moderate to Severe Plaque Psoriasis”, March 2012
- 18 Principal Investigator, Galderma R & D, “A Phase 3 Randomized, Double-blind, 12-week, Vehicle controlled, Parallel-group Study Assessing the Efficacy and Safety of XXX in Subjects with Papulopustular Rosacea, Followed by a 40-week Investigator-blinded Extension Comparing the Long-term safety of XXX”, January 2012
- 19 Principal Investigator, Abbott Laboratories, “A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa”, December 2011
- 20 Principal Investigator, Eli Lilly, “A Multicenter study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of XXX in Patients with Moderate to Severe Plaque Psoriasis”, November 2011
- 21 Principal Investigator, Pfizer, “A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis”, January 2011
- 22 Principal Investigator, Galderma, Inc. “A Study to Evaluate Treatment of Facial Erythema Associated with Rosacea”, March 2011
- 23 Anacor Pharmaceuticals, Inc. “A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults” May 2011

- 24 Principal Investigator, Galderma R & D, Inc. “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group Study Comparing the Efficacy and Safety of CD2475/101 40mg Tablets versus Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions in Subjects with Acne Vulgaris” May 2011
- 25 Photocure ASA. “A double blinded, prospective, randomized, vehicle controlled multi-center study of photodynamic therapy with Visonac® cream in patients with acne vulgaris” July 2011
- 26 Principal Investigator, Therapeutic, Inc. “Blinded Study of Topical Investigational Lotion vs. Approved Cream in Treatment of Plaque Psoriasis”, July 2010.
- 27 Principal Investigator, Leo Pharma, “Leo 80185 in the treatment of Psoriasis Vulgaris on the Non scalp Regions of the Body (Trunk and/or Limbs)”, October, 2010.
- 28 Principal Investigator, Acne study of topical medication, December 2009.
- 29 Principal Investigator, Stiefel Laboratories, Inc. “A multicenter, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of tazarotene foam, 0.1% in subjects with acne vulgaris”, December 2009.
- 30 Principal Investigator, Galderma, Inc. “A phase 4, open-label, multicenter, community-based 12 week trial assessment of effectiveness, safety, and subject satisfaction with Oracea (doxycycline USP) capsules 40 mg (30 mg immediate release, 10 mg delayed release beads) when used as monotherapy or as add on therapy to existing topical regimens for the treatment of rosacea”, February 2009.
- 31 Principal Investigator, Genzyme, “A multi-center, double-blind, placebo-controlled, dose-ranging study to assess the efficacy and safety of doxercalciferol capsules in the treatment of subjects with moderate to severe chronic plaque psoriasis”, March 2009.
- 32 Principal Investigator, Nycomed US Inc. “A multi-center, double-blind, randomized, vehicle-controlled, parallel-group study comparing Nycomed US Inc’s tacrolimus ointment 0.1% to Protopic (tacrolimus) ointment 0.1% and both active treatments to a vehicle control in the treatment of atopic dermatitis”, June 2009.
- 33 Principal Investigator, Nycomed US Inc. “A multi-center, double-blind, randomized, vehicle-controlled, parallel-group study comparing Nycomed US Inc’s tacrolimus ointment 0.3% to Protopic (tacrolimus) ointment 0.3% and both active treatments to a vehicle control in the treatment of atopic dermatitis”, June 2009.
- 34 Principal Investigator, Stiefel Laboratories, Inc. “A phase 3 multicenter, randomized, double-blind, active and vehicle-controlled study of the safety and efficacy of Duac Los-Dose Gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris”, October 2008.
- 35 Principal Investigator, Centocor. “A multicenter open registry of patients with psoriasis who are candidates for systemic therapy including biologics”, March 2008.
- 36 Principal Investigator, Galderma, Inc. “A multi-center, randomized, double-blind, parallel group study to demonstrate the efficacy and safety of adapalene lotion, 0.1%, compared with vehicle lotion in subjects with acne vulgaris”, February 2008.
- 37 Principal Investigator, Centocor. “A multi-center, open-label study to assess the efficacy and safety of Infliximab (Remicade) therapy in patients with plaque psoriasis who had an inadequate response to etanercept (Enbrel)”, September 2007.
- 38 Principal Investigator, PLIVA Research and Development Ltd. “A randomized, double blind, multiple-site, placebo-controlled study comparing mupirocin calcium 2% topical cream to Bactroban (mupirocin calcium) 2% cream (GlaxoSmithKline) in the treatment of secondary infected wounds”, August 2007.
- 39 Principal Investigator, PLIVA Research and Development Ltd. “A randomized, double-blind, multiple-site, placebo controlled, parallel design, clinical study to evaluate the bioequivalence of adapalene cream 0.1% compared to Differin (adapalene 0.1%) topical cream (Galderma) in patients with acne vulgaris.” August 2007.
- 40 Principal Investigator, Galderma, Inc. “A multi-center, randomized, double-blind, parallel-group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris,” January 2007.
- 41 Principal Investigator, Abbott Laboratories. “A randomized, investigator-blind study to evaluate the effectiveness of oral cefdinir (Omnicef) once daily versus oral cephalixin four times daily for the treatment of uncomplicated skin and skin structure infections (USSSIs),” November 2005.
- 42 Principal Investigator, Genentech. “RAPTIVA epidemiologic study of psoriasis outcomes and safety events (RESPONSE) in patients with chronic moderate to severe plaque psoriasis,” March 2005.
- 43 Principal Investigator, Astellas, “APPLES: A prospective pediatric longitudinal evaluation to assess the long-term safety of tacrolimus ointment for the treatment of atopic dermatitis,” November 2005.

- 44 Principal Investigator, Astelles. "Assessment and Tracking of Long-term Alefacept (LFA-3/IgG1 fusion protein) Safety (ATLAS)," June 2005.
- 45 Principal Investigator, Fujisawa. "A phase 3, randomized, double-blind study comparing twice daily FK 506 cream 0.03% versus cream vehicle in the treatment of atopic dermatitis in pediatric subjects," March 2004.
- 4 6 Principal Investigator, Genentech. "An open-label multicenter study to evaluate the safety of 1.0 mg/kg subcutaneous efalizumab in adults with moderate to severe plaque psoriasis including those who are receiving concomitant antipsoriatic therapies or have recently transitioned from systemic therapies." 9/03-6/04.
- 4 7 Co-Investigator, Stiefel. "A multi-center, investigator-blind, vehicle-controlled, non-inferiority study of the safety of Stieprox shampoo compared to Loprox Gel and a superiority study of the efficacy of Stieprox shampoo compared to vehicle shampoo in the treatment of seborrheic dermatitis of the scalp for 4 weeks." 8/03-5/04.
- 4 8 Co-Investigator, Amgen. "A multicenter, open label study to observe the effect of Etanercept on joint and skin disease in subjects with psoriatic arthritis." July 2003.
- 4 9 Principal Investigator, Glaxo-Smith-Kline. "A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Three Dose levels of Rosiglitazone Maleate in the Treatment of Chronic Plaque Psoriasis." November 2002.
- 50 Surgical Investigator, QLT, Inc. "A Randomized, Placebo-Controlled, Masked, Multicenter, Phase III Study of Photodynamic Therapy with Verteporfin for Injection (VFI) for the Treatment of Multiple Basal Cell Carcinomas." 11/02-3/04.
- 51 Principal Investigator, Pfizer, Inc. "An Open Label, Multicenter Trial of Diflucan (Fluconazole) for 6 Weeks Given Once Daily to Pediatric Patients with Tinea Capitis", 10/02-3-03.
- 52 Principal Investigator, Ligand Pharmaceuticals. "A Multicenter, Dose-Randomized Evaluation of Targretin Capsules + PUVA in Patients with Stable IB-IIA Cutaneous T-Cell Lymphoma", 9/02-6/04.
- 53 Principal Investigator, Pfizer, Inc., "A Clinical Study to Evaluate the Efficacy of Fluconazole vs. Griseofulvin in Pediatric Patients with Tinea Capitis", 7-02-3/03.
- 54 Principal Investigator, Novartis, "A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Terbinafine in Patients with Onychomycosis of the Toenail", 10/02-5/03.
- 55 Principal Investigator, Connetics Corporation, "A Clinical Study to Evaluate the Efficacy and Patient Compliance Comparing Beta Methasone Valerate 0.12% Foam to Triamcinolone 0.1% Cream and Lotion for the Treatment of Chronic Mild to Moderate Scalp and Body Psoriasis," 9/1/01-6/30/02.
- 56 Principal Investigator, Fujisawa Healthcare, "An Open Label Study to Evaluate the Safety of Topically Applied Tacrolimus Ointment for the Treatment of Atopic Dermatitis, 12/99-10/00.

PUBLICATIONS:

Original observations in refereed journals

1. Aufiero B, Guo M, Young C, Duanmu Z, Talwar H, Lee HK, Murakawa GJ. Staphylococcus aureus induces the expression of tumor necrosis factor-alpha in primary human keratinocytes. *Int J Dermatol* 2007 Jul; 46(7):687-94.
2. Krasner B, Hamzavi F, Murakawa GJ, Hamzavi I. Dissecting cellulitis treated with the long pulsed Nd:YAG laser. *Dermatologic Surgery* 2006 Aug; 32(8):1039-44.
3. Brewer J, van der Kooi K, Hamzavi I, Murakawa GJ. Systems-base practice for dermatology residency training. Manuscript in preparation.
4. Brewer C, Meduri NB, Radin D, Murakawa GJ, Hamzavi I. Phacomatosis pigmentovascularis: a report of two cases in African Americans. Manuscript in preparation.
5. Nasser FA, Truong S, Scissors B, Murakawa GJ. Topical immunomodulator and topical steroid usage in the United States. Manuscript in preparation.
6. Quinlan K, Scissors B, Krasner B, Aronson P, Murakawa GJ. A comparison of the accessibility of the top 100 prescribed oral medications in Michigan. Manuscript in preparation.
7. Madani S, Murakawa GJ. Combination of O to T with island pedicle flap. Manuscript in preparation.
8. Trepte J, Abdul-Khalek R, Murakawa GJ. Providing dermatological care to the indigent population in Detroit, Michigan, and the United States. Manuscript in preparation.
9. Aufiero BM, Talwar H, Young C, Krishnan M, Hatfield JS, Lee HK, Wong HK, Hamzavi I, Murakawa GJ. Narrow-band UVB induces apoptosis in human keratinocytes. *J Photochemistry and Photobiology* 2005; 82: 132-139.
10. Scher RK, Elston DM, Hedrick JA, Joseph WS, Maurer T, Murakawa GJ. Treatment options in the management of uncomplicated skin and skin structure infections. *Cutis* 2005; 75 (1Suppl): 3-23.
11. Aufiero BM, Duanmu Z, Guo M, Meduri NB, Murakawa GJ, Falkow S. *Staphylococcus aureus* infection of human primary keratinocytes. *J Dermatol Sci* 2004; 36:173-5.

12. Murakawa GJ. Common pathogens and differential diagnosis of skin and soft tissue infections. *Cutis* 2004; 73:S7-10.
13. Murakawa GJ, Lubitz P, Harvell J, Lee S, Schnoll S, Hennessey P, Berger T. Cutaneous aspergillosis in patients with AIDS. *Archives Dermatology* 2000; 136:365-369.
14. Murakawa GJ, Kerschmann R, Berger TG. Vulvar verrucous papules. *Archives Dermatology* 1999; 135:204-205, 207-208.
15. Murakawa GJ, McCalmont T, Frieden IJ. Chronic plaques in a patient with ataxia-telangiectasia. *Archives Dermatology* 1998; 134:1145-1148.
16. Murakawa GJ. Pathogenesis of *Bartonella henselae* in cutaneous and systemic disease. *J Am Acad Dermatol* 1996; 37:775-6.
17. Kao D, Murakawa GJ, Kerschmann R, Berger TG. Cutaneous strongyloidiasis in patients with AIDS: an unusual manifestation in AIDS. *Archives Dermatology* 1996; 132:977-978.
18. Murakawa GJ, Kerschmann R, Berger TG. Cutaneous *Cryptococcus* and AIDS: report of 12 cases and review of the literature. *Archives Dermatology* 1996; 132:545-548.
19. Murakawa GJ, McCalmont T, Altman J, Telang GH, Hoffman MD, Kantor GR, Berger TG. Disseminated acanthamoebiasis in patients with AIDS: A report of five cases and a review of the literature. *Archives Dermatology* 1995; 131:1291-1296.
20. Murakawa GJ, Mauro TM, Egbert B. Cutaneous *Cryptococcus* mimicking basal cell carcinoma. *Dermatologic Surgery* 1995; 21:992-993.
21. Schnetzler B, Murakawa G, Abalos D, Halban P, Selden R. Adaptation to supraphysiologic levels of insulin gene expression in transgenic mice: evidence for the importance of posttranscriptional regulation. *J Clin Invest.* 1993; 92:272-280.
22. Murakawa GJ, Kwan C, Yamashita J, Nierlich DP. Transcription and decay of the *lac* messenger: role of an intergenic terminator. *J Bacteriol.* 1991; 173:28-36.
23. Murakawa GJ, Nierlich DP. Mapping the *lacZ* ribosome binding site by RNA footprinting. *Biochemistry.* 1989; 28:8067-8072.
24. Murakawa GJ, Chen C-hB, Kuwabara MD, Nierlich DP, Sigman DS. Scission of RNA by 1,10-phenanthroline-copper ion: preference for single-stranded loops. *Nucleic Acids Research.* 1989; 17:5361-5375.
25. Murakawa GJ. Regulatory sites of translation and messenger decay of the *E. coli lac* Operon. 1988; Ph.D. Thesis. University of California, Los Angeles.
26. Murakawa GJ, Zaia JA, Spallone PA, Stevens DA, Wallace RB, Rossi JJ. Direct detection of HIV-1 RNA from AIDS and ARC patient samples. *DNA.* 1988; 7:287-295.
27. Zaia JA, Rossi JJ, Murakawa GJ, Spallone PA, Stevens DA, Kaplan BE, Erjita R, Wallace RB, Cantin EM. Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targeted to the *tat-III* Gene. *J. Virology.* 1988; 62:3914-3917.
28. Murakawa GJ, Nierlich DP. Expression of a tRNA Gene in the context of the *lacZ* mRNA. *J Bacteriology.* 1987; 169:546-552.

Review articles

1. Murakawa GJ, Aufiero BM. Microflora and bacterial infections of the skin. *Skin and Aging*, 2005; 13:45-50.
2. Sable D, Murakawa GJ. Quinolones in Dermatology, *Dis Mon*, 2004; 50:381-94.
3. Sable D, Murakawa GJ. Quinolones in Dermatology, *Clinics in Dermatology*, 2003; 21:56-63.
4. Murakawa GJ, LeBoit PE. *Bartonella henselae* causes bacillary angiomatosis and cat scratch disease. *J Molecular Medicine*, in preparation.
5. Chiller K, Selkin BA, Murakawa, GJ. Skin microflora and bacterial infections of the skin. *J Investigative Dermatology Symposium Proceedings*, 6:170-174, 2001.
6. Nierlich DP, Murakawa GJ. The decay of bacterial messenger RNA. *Prog Nucl Acids Mol Biol.* 1996; 52:153-216.

Books and chapters

1. Wiener, A, Murakawa GJ. Cat Scratch Disease. In: *Treatment of Skin Disease: Comprehensive therapeutic strategies*, Lebwohl M et al., 3rd ed, in press.
2. Hamzavi F, Murakawa GJ. Topical medications. In: *Neonatal and Pediatric Pharmacology, 3rd Edition*. Yaffe SJ, Aranda JV eds, in press.
3. Thomas L, Chan H, Murakawa GJ. Urticaria. In: *Dermatologia Practica: Atlas, Patologia, Sistemica Asociada y Terapeutica*, Mihm M, Camacho F, Torres V, Sober A eds, in press.
4. Abdul-Khalek R, Murakawa GJ. Miscellaneous bacterial infections with skin manifestations: Verruga peruana, Bartonellosis. In: *Dermatologia Practica: Atlas, Patologia, Sistemica Asociada y Terapeutica*, Mihm M, Camacho F, Torres V, Sober A eds, in press.
5. Selkin BA, Murakawa GJ. Cat Scratch Disease. In: *Treatment of Skin Disease: Comprehensive therapeutic strategies*, Lebwohl M et al., 2002, eds, pp 106-108.

6. Murakawa GJ, Berger TG. Chapter 199: Bartonellosis. In: *Dermatology in General Medicine, 5th Edition*, Fitzpatrick TB et al., eds. pp 2249-56.
7. Nierlich DP, Kwan C, Murakawa GJ, Mahoney PA, Ung AW, Caprioglio D. Intercistronic sites in the *lac* operon. In: *The Molecular Biology of Bacteria Growth*. M. Schaechter, F. C. Neidhardt, J. L. Ingraham and N. O. Kjeldgaard (eds.) Jones and Bartlett, Boston. 1985; pp. 185-193

Patents

Serial Number 07/402,450

Title: Method for Amplification and Detection of RNA sequences

PUBLISHED ABSTRACTS:

1. Duanmu Z, Aufiero BM, Murakawa GJ. Profiling *Staphylococcus aureus*-mediated proinflammatory cytokine response in keratinocytes. *J. Invest Dermatol* 2004; 122:A084.
2. Nasser FA, Huynh PM, Murakawa GJ. Topical immunomodulators and topical steroids usage in the U.S. for inflammatory dermatoses. *J. Invest Dermatol* 2004; 122:A320.
3. Yeung-Yue KA, Adul-Khalek R, Trepte J, Murakawa GJ. The impact of managed care to dermatologists when providing care for the indigent population. *J. Invest Dermatol* 2004; 122:A392.
4. Quinlan KE, Krasner BD, Yeung-Yue KA, Murakawa GJ. Availability of the top 100 prescribed topical medications in private insurance, Medicaid, and VA formularies in Michigan. *J. Invest Dermatol* 2004; 122:A394.
5. Murakawa GJ, Quinlan KE, Krasner BD, Aronson PA. A comparison of the accessibility of the top 100 prescribed oral medications in Michigan. *J. Invest Dermatol* 2004; 122:A395.
6. Aufiero BM, Duanmu Z, Murakawa GJ. Specification of *Staphylococcus aureus* infection requirements for TNF- α induction. *J. Invest Dermatol* 2004; 122:A807.
7. Young CN, Aufiero BM, Murakawa GJ. *Staphylococcus aureus*-induced apoptosis in primary human keratinocytes. *J. Invest Dermatol* 2004; 122:A812.
8. Hamzavi I, Deleon S, Yeung-Yue K, Murakawa G. What is the maximum tolerated dose of NG-UVB for patients with vitiligo? *J. Invest Dermatol* 2004; 122:A938.
9. Guo M, Yao D, Murakawa GJ. *Staphylococcus aureus* induces TNF- α expression in human keratinocytes. *J. Invest Dermatol* 2003; 121: P0114.
10. Murakawa GJ, Abdul-Khalek R, Trepte J. Providing dermatological care to the indigent population. *J. Invest Dermatol* 2003; 121: P0462.
11. Abdul-Khalek R, Trepte J, Murakawa GJ. Utilization of resources in a practice that provide care to private pay and indigent patients. *J. Invest Dermatol* 2003; 121: P0463.
12. Duanmu Z, Aufiero B, Zhen H, Falkow S, Tompkins LS, Murakawa GJ. *Staphylococcus aureus* infection of primary cultured human keratinocytes: a morphological approach. *J. Invest Dermatol* 2003; 121: P1054.
13. Aufiero B, Yao D, Murakawa GJ. *Staphylococcus aureus* invade and replicate in epidermal and dermal cells. *J. Invest Dermatol* 2003; 121: P1056.
14. Murakawa G, Guo M, Meduri N, Yao D. Pathogenesis of *Staphylococcus aureus* in skin infections. *Ann Dermatol Venereol* 2002; 129: S542. P0894.
15. Sable D, Murakawa G. Cutaneous Brucellosis. *Ann Dermatol Venereol* 2002; 129: S545. P0907.
16. Guo M, Meduri N, Yao D, Murakawa G. *Staphylococcus aureus* induces interleukin-8 expression in primary human keratinocytes. *J Invest Derm* 2002.
17. Shraga A, Mehregan DR, Rahbari H, Murakawa GJ. Primary cutaneous endometrioma. Gross and Microscopic Session, AAD 2002.
18. Krasner BD, Pegouske D, Rahbari H, Murakawa GJ. Liposomal doxorubicin induced intertrigo-like eruption. Gross and Microscopic Session, AAD 2002.
19. Radin DA, Murakawa GJ. Systemic lupus erythematosus and albinism in an African-American woman. Gross and Microscopic Session, AAD 2002.
20. Dock BS, Murakawa GJ. Destructive Herpetic whitlow. Gross and Microscopic Session, AAD 2002.
21. Sable DB, Murakawa GJ. Cutaneous Brucellosis mimicking granuloma annulare. Gross and Microscopic Session, AAD 2002.
22. Kadry R, Murakawa G, Pegouske D, Mehregan DA. Verrucoid vulvar lesions. Gross and Microscopic Session, AAD 2002.
23. Moossavi, M, Xue, W, Murakawa, GJ. Lichen Aureus Involving the Hands and Feet. AAD Academy 2001, Aug. 2001.
24. Meduri, NB, Yao, D, Murakawa, GJ. The Interactions of *Staphylococcus aureus* with Murine Langerhans Cells. Society for Investigative Dermatology Annual Meeting, May 2001.

25. Selkin B, Murakawa GJ, Carlson JA. *Capnocytophaga canimorsus* Sepsis Presenting as Bilateral Fixed Livedo Reticularis. Gross and Microscopic Session, AAD 2001.
26. Barthelette SC, Carlson JA, Murakawa GJ. Cutaneous *Cryptococcus neoformans* Leading to a Diagnosis of HIV. Gross and Microscopic Session, AAD 2001.
27. Parisi MB, Murakawa GJ, Wharton J. Multiple Juvenile Xanthogranulomas and Café-au-lait Macules. Gross and Microscopic Session, AAD 2001.
28. Parisi MB, Murakawa GJ, Carlson JA Drug-Induced (Trimethoprim/Sulfamethoxazole) Linear IgA Disease with Mucosal Involvement. Gross and Microscopic Session, AAD 2000.
29. Martinez S, Murakawa GJ, Carlson JA. A Woman with Ulcerating Cutaneous Sarcoidosis. Gross and Microscopic Session, AAD 2000.
30. Murakawa GJ. Pathogenesis of *Staphylococcus aureus* in cutaneous disease. Residents and Fellows Symposia, AAD 1999.
31. Badia AA, Murakawa GJ, Carlson JA. A pregnant woman with pemphigus. Gross and Microscopic Session, 1999 AAD.
32. Martinez S, Murakawa GJ, Carlson JA. A woman with CHILD syndrome. Gross and Microscopic Session, 1999 AAD.
33. Murakawa GJ, Lee A, Tompkins LS, Falkow S. Pathogenesis of *Bartonella henselae* in cutaneous and systemic disease. *Australasian J Dermatol* 1997; 38: S231
34. Murakawa GJ, Lee A, Tompkins LS, Falkow S. Invasion of *Bartonella henselae* into mammalian cells. *J Inv Dermatol* 1997; 108:676.
35. Murakawa GJ, Peek JA, Tompkins LS, Falkow S. Sequence and characterization of an invasion locus in *Bartonella henselae*. *J Inv Dermatol* 1996; 106:914.
36. Murakawa GJ, Peek JA, Tompkins LS, Falkow S. Sequence and characterization of an invasion locus in *Bartonella henselae*. 12th Sesqui-Annual meeting of the American Society for Rickettsiology and Rickettsial Diseases, March 1996.
37. Murakawa GJ, Golabi M, Williams M. An infant with Beare-Stevenson Syndrome. Gross and Microscopic Session, 1996 AAD.

PRESENTATIONS:

Invited/refereed international meetings

1. Session Chair, Infectious Diseases, IX International Congress of Dermatology, Beijing, China, 5/21/04
2. *Staphylococcus aureus* and *Streptococcus pyogenes* Skin Infections, ICD, Beijing, China, 5/21/04

Invited/refereed national meetings

1. Managing Your Staph, Focus Session, American Academy of Dermatology Annual Meeting, San Francisco, CA, 3/7/9.
2. Abbott Immunology Psoriasis Clinical Advisory Board Meeting, Rosemont, IL, 5/30-31/8
3. Case studies: applying the treatment algorithm to manage the most common uncomplicated skin and skin structure infections. Uncomplicated skin and skin structure infections speaker training meeting. Las Colinas, TX, 2/26/5.
4. Health Policy Update, Focus Session, American Academy of Dermatology Annual Meeting, New Orleans, LA, 2/18/5.
5. The use of cephalosporins to treat uncomplicated skin and skin-structure infections. Symposia, Academy 2004, NYC, NY, 7/28/4
6. Infections in Immunocompromised Patients, Focus Session, Academy 2004, NYC, NY, 7/29/4
7. Program Chair, Dermatology Speaker Training Program: Antibiotic Treatment Options for Uncomplicated Skin and Skin-Structure Infections, Las Vegas, May 14-16, 2004
8. Oral Cephalosporins for Uncomplicated Skin and Skin-structure Infections: Case Study Related, Las Vegas, 5/15/04
9. Treatment Algorithms for Uncomplicated Skin and Skin Structure Infections, Las Vegas, 5/15/04
10. Health Policy Update, Focus Session, American Academy of Dermatology Annual Meeting, Washington, DC, 2/8/4
11. Common Pathogens and Differential Diagnosis of Skin and Soft Tissue Infections, Dermatology Update: Focus on Skin and Soft Tissue Infections, Chicago, IL 11/22/3
12. Immunity to Infectious Diseases, 8th Annual Intro. to Cutaneous Biology Course, Indiana U, Indianapolis, IN 11/7/3
13. Combination Therapy for Atopic Dermatitis, Hot Spots in Dermatology, Maui, HI, 8/17/03
14. Providing Dermatological Care to the Indigent Population, Hot Spots in Dermatology, Maui, 8/16/03
15. Providing Dermatological Care to the Indigent Population, Internat. Investigative Dermatol. Meeting, Miami, FL 5/3/03
16. Skin Microflora and Bacterial Infections of the Skin, Focus Session, American Academy of Dermatology Annual Meeting, San Francisco, CA 3/24/03
17. Moderator, Great Lakes Roundtables, Ferndale Laboratories, Las Vegas, NV10/11/02
18. Out Damned Spot, Out I Say, Great Lakes Roundtables, Ferndale Laboratories, Las Vegas, NV10/11/02
19. Not All Vehicles are Equal, Great Lakes Roundtables, Ferndale Laboratories, Las Vegas, NV10/11/02
20. Infections in Immunocompromised Patients, Focus Session, Academy 2002, NYC, NY, 8/3/02

21. Skin Microflora and Bacterial Infections of the Skin, Focus Session, American Academy of Dermatology Annual Meeting, New Orleans, LA 2/24/02
22. Combination Therapy for Atopic Dermatitis, 26th Annual Hawaii Dermatology Seminar, Maui, HI 2/1/02
23. The End of Itch: Novel New Immunomodulators and Atopic Dermatitis, Hot Spots in Dermatology, Big Island, HI, 8/18/01
24. Practical Experiences with Tacrolimus, Hot Spots in Dermatology, Big Island, HI, 8/18/01
25. Bacterial Skin Infections, Montagna Symposia, Snowmass, CO, 8/00
26. What's New in *Bartonella*: Bacillary Angiomatosis, Cat Scratch Disease Update. AIDS Symposia, American Academy of Dermatology Meeting, San Francisco, CA, 3/97.
27. Cutaneous *Cryptococcus* and AIDS. San Francisco Dermatology Society. 1/95.

Invited/refereed local/regional meetings

1. Diagnosis and Management of Common Dermatologic Conditions, Practical Update in Primary Care Medicine:2008, William Beaumont Hospitals, Troy, MI, 4/18/08
2. Turning back the clock: skin cancers, anti-aging therapy. 8th Annual Urban Hypertension Update, DVAMC, Detroit, MI, 6/11/5.
3. Biologic therapies for psoriatic disease: current applications and future strategies, Cincinnati, OH, 2/25/4.
4. Biologic therapies for psoriatic disease: current applications and future strategies, Cleveland, OH, 2/23/4.
5. Workshop on working up a diagnosis in common medical problems, Dermatology in Primary Care: Update 2003, St. John Hospital, MI, 10/15/3
6. Skin Microflora and Bacterial Infections of the Skin, Grand Rapids Dermatology Journal Club, Grand Rapids, MI, 11/21/02
7. Indigent Care in Dermatology, Michigan Dermatological Society Meeting, WSU, 11/20/02
8. Disseminated Acanthamoebiasis and AIDS. University of California Dermatology Meeting, Lake Tahoe, CA. August 1994.
9. Atopic Dermatitis Overview: Pathophysiology, Epidemiology, and Management. Managed Care Advisory Meeting, Indianapolis, IN 12/5/01

Invited seminars and lectures

1. Common Dermatological Conditions in the Elderly. Grand rounds, PMDs in Southfield, MI 2/15/5.
2. Onychomycosis: Epidemiology, Diagnosis, and Management, Dermatology Grand Rounds, Marshfield Clinic, WI
3. State of the Department Address, Dermatology Grand Rounds, WSU 7/2/4
4. Health Policy Update, Dermatology Grand Rounds, WSU, 4/04
5. Dermatologic Surgery: Great Cases at WSU, Otolaryngology Grand Rounds, WSU, 2/19/4
6. Common Dermatological Conditions, Physical Medicine & Rehabilitation Grand Rounds, WSU, 1/23/4
7. Biologic Therapies for Psoriatic Disease: Strategies for Optimizing Patient Outcomes, Amgen, 9/29/3
8. State of the Dept Address, Dermatology Grand Rounds, WSU, 7/3/03
9. Infections in Immunocompromised Patients, Dermatology Grand Rounds, WSU, 10/16/02
10. Herpes Simplex, GlaxoSmithKline, Detroit, 8/14/02
11. Skin Microflora and Skin Infections, Pediatrics Grand Rounds, Children's Hospital, WSU, 8/9/02
12. State of the Dept Address, Dermatology Grand Rounds, WSU, 7/10/02
13. Onychomycosis: What you and your patients want from nail fungal infection treatments. Novartis Advisory Board Meeting, Troy, MI, 6/13/02
14. New Dimensions in the Treatment of Herpes Virus Infections. Novartis Advisory Board Meeting, Pontiac, MI, 6/11/02.
15. Onychomycosis: What you and your patients want from nail fungal infection treatments. Novartis Advisory Board Meeting, Flushing, MI, 5/23/02
16. New Dimensions in the Treatment of Herpes Virus Infections. Novartis Advisory Board Meeting, Flushing, MI, 5/9/02.
17. New Dimensions in the Treatment of Herpes Virus Infections. Novartis Advisory Board Meeting, Troy, MI, 4/10/02.
18. Skin Flora/Bacterial Infections-Skin, Medicine Grand Rounds, St John's Hospital, Grosse Pointe, MI 4/13/02
19. Common Dermatology Consults in the Pediatrics Emergency Department, Emergency Medicine Conference, WSU, 4/3/02
20. Update in AIDS Dermatology, Resident Teaching Conference, University of California, Irvine, 3/26/02
21. Skin Microflora and Bacterial Infections of the Skin, Resident Teaching Conference, Univ. California, Irvine, 3/26/02
22. Skin Tumors of the Head and Neck, Otolaryngology Grand Rounds, Wayne State University, 2/13/02
23. Update in AIDS Dermatology, Dermatology Grand Rounds, Wayne State University, 1/23/02
24. Understanding the Changing Landscape of Eczema Treatment, Novartis Advisory Board Meeting, Bloomfield, MI, 1/22/02
25. Cutaneous Cryptococcosis, Dermatology Grand Rounds, WSU, 9/19/01
26. Common Dermatology Hospital Consultations, PM & R Grand Rounds, WSU, 9/14/01

27. Interesting Cases with Clinical-Pathological Correlation, Dermatology Grand Rounds, WSU, 9/12/01
28. Herpes Infections, Novartis Pharmaceuticals, Birmingham, MI, 7/25/01
29. Herpes Infections, Novartis Pharmaceuticals, Flint, MI, 7/27/01
30. State of the Dept Address, Dermatology Grand Rounds, WSU, 7/11/01
31. Herpes Infections, Dermatology Grand Rounds, WSU, 5/30/01
32. Skin Flora/Bacterial Infections-Skin, Medicine Grand Rounds, Beaumont Hospital, Royal Oaks, MI 5/2/01
33. Pathogenesis of *Staphylococcus aureus* in Cutaneous Disease, Grand Rounds, Dept Anatomy, WSU, 3/15/01
34. CTCL: A Dermatologist's Perspective, Grand Rounds, Karmanos Cancer Institute, WSU, 3/8/01
35. Skin Microflora and Bacterial Infections of the Skin, Dermatology Grand Rounds, WSU, 2/21/01
36. Bartonella Infections, Dermatology Grand Rounds, Wayne State University, 9/20/00
37. Atopic Dermatitis, Dermatology Grand Rounds, Albany Medical College, 1/26/00
38. Cutaneous Manifestations of HIV, Dermatology Grand Rounds, Wayne State University, 1/13/00
39. Cutaneous Manifestations of HIV, Dermatology Grand Rounds, University of Wisconsin, Madison, 12/14/99
40. Unusual Dermatologic Presentations at Albany Medical College, Stanford Dermatology Rounds, 5/7/99
41. Uncommon Cutaneous Manifestations in AIDS Patients, Dermatology Grand Rounds, AMC, 8/4/99
42. Tumors of the Skin, PA program, AMC, 6/7/99
43. Cutaneous Manifestations in Lupus, Dermatology Grand Rounds, AMC, 4/7/99
44. Cutaneous Manifestations in Lupus, Rheumatology Grand Rounds, AMC, 3/30/99
45. Unusual Dermatological Presentations at Albany Medical College, UCSF Dermatology Rounds, 12/4/98
46. Bartonella Infections, Dermatology Grand Rounds, AMC, 11/18/98
47. Cutaneous Manifestations of Cryptococcus, Dermatology Grand Rounds, AMC, 10/7/98
48. Skin Tumors, Medicine resident conference, AMC, 9/30/98
49. Unusual Dermatological Presentations at Albany Medical College, Stanford University Dermatology Rounds, 8/98
50. Dermatological Presentations at Albany Medical College, UCSF Dermatology Rounds, 8/98
51. ABC's of Dermatology, Medicine resident conference, AMC, 8/98
52. Superficial Fungal Infections, Albany Marriott (sponsored by Novartis Pharmaceuticals), 12/10/98
53. Development of Cutaneous Models to Study Bacterial Pathogenesis. Dermatology Grand Rounds, University of California, San Francisco, May 1998
54. Pathogenesis of *Bartonella henselae* in Cutaneous and Systemic Disease. Dermatology Grand Rounds, University of Texas, Southwestern, January 1998.
55. Pathogenesis of *Bartonella henselae* in Cutaneous and Systemic Disease. Dermatology Grand Rounds, Emory University, November 1997.
56. Cutaneous Manifestations of AIDS. Dermatology Grand Rounds, Emory University, November 1997.
57. Cutaneous Manifestations of AIDS. Pathology Grand Rounds. Albany Medical College, July 1997.
58. Cutaneous Manifestations of AIDS. Dermatology Grand Rounds. University of South Florida, August 1997.
59. Disseminated Acanthamoebiasis and AIDS. San Francisco Dermatology Society. January 1994.